Successful use of cytarabine and bendamustine in a patient with mantle cell lymphoma and acute renal failure using intermittent hemodialysis: A case report

Abstract

Mantle cell lymphoma is a mature B-cell non-Hodgkin lymphoma characterized by the hallmark (11;14) chromosomal translocation, which often presents with lymphadenopathy and extra-nodal involvement. Young, fit patients are generally treated with chemotherapy approaches that incorporate high-dose cytarabine (e.g. the Nordic regimen) followed by autologous hematopoietic cell transplantation. Because of the significant activity of cytarabine in mantle cell lymphoma, increasingly, high- and intermediate-dose cytarabine are being used in the treatment of elderly mantle cell lymphoma patients. In practice, many patients present with significant organ dysfunction and there is limited data on the use of high- to intermediate-dose cytarabine and bendamustine in this setting. Here, we report a case of a critically ill, elderly patient with mantle cell lymphoma and concomitant acute kidney injury and oliguria who was successfully treated with a cycle of cytarabine (Ara-C) and bendamustine accompanied by intermittent hemodialysis.

Keywords

Mantle cell lymphoma acute renal failure hemodialysis cytarabine bendamustine

Get full access to this article

View all access options for this article.

References

Jares

Colomer

Campo

. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer 2007; 7: 750–750.

Herrmann

Hoster

Zwingers

et al.

Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 2008; 27: 511–518.

Geisler

Kolstad

Laurell

et al.

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo–purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008; 112: 2687–2693.

Romaguera

Fayad

Rodriguez

et al.

High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005; 23: 7013–7023.

Rummel

Niederle

Maschmeyer

et al.

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. The Lancet 2013; 381: 1203–1210.

Flinn

van der Jagt

Kahl

et al.

Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood 2014; 123: 2944–2952.

Robak

Huang

Jin

et al.

Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med 2015; 372: 944–953.

Visco

Chiappella

Nassi

et al.

Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi. Lancet Haematol 2017; 4: e15–e23.

Branca

Gianesello

Brugnaro

et al.

Rituximab-bendamustine cytarabine (R-BAC) as frontline therapy in mantle cell lymphoma: a single-center experience. Blood 2015. 126:2710.

10.

Lindner

Ostermann

Hiddemann

et al.

AraU accumulation in patients with renal insufficiency as a potential mechanism for cytarabine neurotoxicity. Int J Hematol 2008; 88: 381–386.

11.

Damon

Mass

Linker

. The association between high-dose cytarabine neurotoxicity and renal insufficiency. J Clin Oncol 1989; 7: 1563–1568.

12.

Worden FP, Perissinotti AJ, Marini BL. Cancer pharmacology and pharmacotherapy review: study Guide for Oncology Boards and MOC Exams. New York: Demos Medical Publishing, 2016.

13.

Chim

Kwong

. Cerebellar toxicity with medium-dose cytarabine in a young patient with renal insufficiency. Am J Hematol 1996; 53: 208–208.

14.

Hasle

. Cerebellar toxicity during cytarabine therapy associated with renal insufficiency. Cancer Chemother Pharmacol 1990; 27: 76–78.

15.

Radeski

Cull

Cain

et al.

Effective clearance of Ara-U the major metabolite of cytosine arabinoside (Ara-C) by hemodialysis in a patient with lymphoma and end-stage renal failure. Cancer Chemother Pharmacol 2011; 67: 765–768.

16.

Estey

Plunkett

Gandhi

et al.

Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. Leuk Lymphoma 1993; 9: 343–350.

17.

Nordstrom

Knopf

Teltsch

et al.

The safety of bendamustine in patients with chronic lymphocytic leukemia or non-Hodgkin lymphoma and concomitant renal impairment: a retrospective electronic medical record database analysis. Leuk Lymphoma 2014; 55: 1266–1273.

18.

Pönisch

Moll

Bourgeois

et al.

Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure. J Cancer Res Clin Oncol 2013; 139: 1937–1946.

19.

Shoji

Lew

. The use of rituximab and bendamustine in treating chronic lymphocytic leukaemia (CLL) in end-stage renal disease (ESRD). BMJ Case Rep 2013; 2013: bcr2013009637–bcr2013009637.